PPARG and hepatocellular carcinoma: These drugs activate peroxisome proliferator-activated receptor gamma (PPARγ), which enhances insulin sensitivity, reduces liver steatosis, and has anti-inflammatory effects, which may contribute to a reduced risk of HCC [118].